Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
Part of paid clinical trials in Long Beach, California.
- Sponsor
- VA Office of Research and Development
- Study ID
- NCT06671613
- Status
- Recruiting
Conditions
- Fasting Mimicking Diet
- Immunotherapy
- NSCLC
- Stage IV NSCLC
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- FMD — DIETARY_SUPPLEMENTPlant-based diet program
- Regular Diet Plus FMD — COMBINATION_PRODUCTPatients will eat a RD with the first 3 cycles, then receive 3 cycles of FMD as they continue cycles 4-6
Study Details
The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.
Key Dates
- Start date
- Oct 27, 2025
- Status verified
- Nov 2025
- Primary completion
- Dec 31, 2029
- Completion
- Dec 31, 2030
Study Design
- Enrollment
- 66 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Active Comparator: Regular DietPatients will eat a RD with the first 3 cycles, then receive 3 cycles of FMD as they continue cycles 4-6.
- Experimental: FMDPlant based diet program.
Primary Outcome Measure
Feasibility of fasting mimicking diet intervention [ Time Frame: Through study completion up to 2 years. ]
Central Contacts
- Shadia Jalal, MD(317) 274-5500
- Aleksandra Radovanovich, RN(317) 988-3338
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| VA Long Beach Healthcare System, Long Beach, CA | Long Beach | California | 90822 | |
| Jesse Brown VA Medical Center, Chicago, IL | Chicago | Illinois | 60612 | |
| Richard L. Roudebush VA Medical Center, Indianapolis, IN | Indianapolis | Indiana | 46202-2884 | Shadia Jalal, MD (PRINCIPAL_INVESTIGATOR) |
| St. Louis VA Medical Center John Cochran Division, St. Louis, MO | St Louis | Missouri | 63106-1621 |
Find similar trials in Long Beach, CA
By condition
By specialty
Related Studies
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsPHASE2 · Recruiting · Apollomics Inc. · Los Angeles, California
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung CancerPHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Birmingham, Alabama
- Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLCPHASE3 · Recruiting · Maximilian Diehn · Stanford, California